Fluticasone/salmeterol
Formulation used in the management of asthma and chronic obstructive pulmonary disease / From Wikipedia, the free encyclopedia
Fluticasone/salmeterol, sold under the brand name Advair among others, is a fixed-dose combination medication containing fluticasone propionate and salmeterol.[2] It is used in the management of asthma and chronic obstructive pulmonary disease (COPD).[2] It is used by inhaling the medication into the lungs.[2]
Combination of | |
---|---|
Fluticasone propionate | Glucocorticoid |
Salmeterol | Long-acting β2 agonist (LABA) |
Clinical data | |
Trade names | Advair, Seretide, Cyplos, others |
AHFS/Drugs.com | FDA Professional Drug Information |
MedlinePlus | a699063 |
License data | |
Pregnancy category |
|
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider |
|
KEGG | |
(verify) |
Common side effects include thrush, headache, and cough.[3] Serious side effects may include worsening asthma, anaphylaxis, seizures, and heart problems.[3] Safety in pregnancy and breastfeeding is unclear.[4] Fluticasone, a corticosteroid, works by decreasing inflammation while salmeterol, a long-acting beta-adrenoceptor agonist (LABA), works by activating beta-2 adrenergic receptors.[3]
The combination was approved for medical use in the United States in 2000.[3] A generic version was approved in the United States in 2019.[5] In 2021, it was the 64th most commonly prescribed medication in the United States, with more than 10 million prescriptions.[6][7]